Mainboard · BSE and NSEDraft filed
IBERIA PHARMACEUTICALS INDIA LIMITED IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- 64,75,560 shares (Amount not stated in the draft)
- DRHP dated Sat 5 Sep 2026, page 1
- Bid dates
- Not announced
- Listing date
- Not announced
- Risk factors
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedThu 17 Sep 2026 confirmedDRHP dated Sat 5 Sep 2026
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Capital expenditure towards the procurement of plant & machinery for the establishment of our manufacturing facility in Haryana, India | ₹34.90 crore |
| Repayment of all or a portion of certain outstanding borrowings availed by our Company | ₹12.00 crore |
| Branding and marketing expenses towards enhancing the awareness and visibility of our products and brand | ₹16.90 crore |
| Funding the working capital requirements of our Company | ₹31.00 crore |
| General Corporate Purposes | Not stated in the draft |
| Total | Not stated in the draft |
DRHP dated Sat 5 Sep 2026, page 109
Company and promoters
As described in the DRHP
We are an Indian pharmaceutical and derma cosmetics company with a select portfolio of products across aesthetic dermatology, hair care, cardio diabetic and general therapeutics, offering solutions for a wide range of skin, hair, cardiovascular, diabetic and anti-aging concerns.
DRHP dated Sat 5 Sep 2026, page 195
Promoters
- 4 individual promoters
DRHP dated Sat 5 Sep 2026, page 277
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 97.59% | Not stated in the DRHP |
DRHP dated Sat 5 Sep 2026, page 104
Financials (restated)
| Item | March 31, 2026 | March 31, 2025 | March 31, 2024 |
|---|---|---|---|
| Revenue from operations | ₹96.54 crore | ₹86.72 crore | ₹69.36 crore |
| Profit after tax | ₹11.13 crore | ₹14.19 crore | ₹7.82 crore |
| Net worth | ₹51.65 crore | ₹39.95 crore | ₹14.62 crore |
| Total borrowings | Not stated in the draft | Not stated in the draft | Not stated in the draft |
DRHP dated Sat 5 Sep 2026, page 79
Peer comparison (as in the DRHP)
| Name of the Company | Face Value (₹ per share) | Closing Price as on September 02, 2026 (₹ per share) | Revenue from operations for Financial Year 2026 (in ₹ Lakhs) | Basic Earnings per share for Financial Year 2026(₹)(1) | Net Asset Value per Equity share as on March 31, 2026(2) | P/ E Ratio for the Financial year 2026(3) | Return on capital employed for the Financial year 2026(4) |
|---|---|---|---|---|---|---|---|
| Iberia Pharmaceuticals India Limited | 10.00 | NA | 9,653.7 | 5.73 | 26.59 | NA | 19.85 |
| Eris Lifesciences Limited | 1.00 | 1,335 | 3,12,942 | 45.33 | 281.64 | 29.45 | 14.1 |
| Torrent Pharmaceuticals Limited | 5.00 | 5,004.00 | 13,98,000 | 63.92 | 247.87 | 78.29 | 15.2 |
Reproduced from the DRHP dated Sat 5 Sep 2026, page 136; InsightPier adds no figures
Risk factors
- Most revenue comes from the top two brands (DRHP page 27)
- Business depends on exclusive distribution arrangements with brand owners and suppliers (DRHP page 28)
- The company makes none of its products and relies on third-party manufacturers (DRHP page 29)
- Distributing imported products exposes the company to liability and regulatory risks (DRHP page 31)
- Supply disruptions or cost increases for raw materials and finished products could hurt the business (DRHP page 31)